Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy

Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Heineman, David J., Daniels, Johannes M., Schreurs, Wilhelmina H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564882/
https://www.ncbi.nlm.nih.gov/pubmed/29081843
http://dx.doi.org/10.1177/1758834017722746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564882/
https://www.ncbi.nlm.nih.gov/pubmed/29081843
http://dx.doi.org/10.1177/1758834017722746

Ejemplares similares